Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab182964-100μg
|
100μg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$119.90
|
|
|
Ab182964-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$559.90
|
|
|
Ab182964-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,399.90
|
|
|
Ab182964-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$2,239.90
|
|
Purity≥95% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Frexalimab (anti-CD40L) - Primary antibody, specific to CD40LG, Human IgG1 |
|---|---|
| Synonyms | HIGM1 | T-B cell-activating molecule | T-BAM | T-cell antigen Gp39 | TNF-related activation protein | TNFSF5 | TNFSF5IMD3 | TRAP | TRAPtumor necrosis factor (ligand) superfamily, member 5 (hyper-IgM syndrome) | tumor necrosis factor (ligand) superfamily m |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Biochemical and Physiological Mechanisms | Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL-4. Involved in immunoglobulin class switching. Release of soluble CD40L from platelets is partially regulated by GP IIb/IIIa, actin polymerization, |
| Host species | Human |
| Specificity | CD40LG |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Product Description |
Frexalimab (anti-CD40L) is a monoclonal antibody targeting the CD40 ligand (CD40L). Frexalimab (anti-CD40L) has the potential for multiple sclerosis research.
|
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 145.66 kDa |
| Purification Method | Protein A purified |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| CAS | 2515463-86-0 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Frexalimab (anti-CD40L) (Ab182964) - Flow Cytometry
Flow Cytometry analysis of unstimulated (left) or 500 ng/mL Ionomycin (I139530) and 10 ng/mL PMA (P408905) co-stimulated (right) Jurkat cells labelling CD40L (red) with Frexalimab (anti-CD40L) (Ab182964) at 0.1 μg/mL for 1 hour at 4°C. Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Frexalimab (anti-CD40L) (Ab182964) - SEC
The purity of Frexalimab (anti-CD40L) (Ab182964) is more than 95% verified by HPLC.
Frexalimab (anti-CD40L) (Ab182964) - ELISA
Immobilized Recombinant Human CD40 Ligand/TNFSF5 protein (rp189423) at 1.0 μg/mL can bind Frexalimab (anti-CD40L) (Ab182964) with the EC
₅₀
of 16.93 ng/mL.
Starting at $59.90
Starting at $49.90
Starting at $49.90
Starting at $59.90
Starting at $69.90